Biologics & mAb CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

Biologics / mAb manufacturers on CDMO Signal: 71 listed, 28 with a Signal Score. Together they have 105 FDA inspections on file (including 32 NAI, 72 VAI and 1 OAI), 3 FDA warning letters and 235 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. The score does not measure expression host, validated bioreactor scale, or whether fill-finish is on the same site. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Biologics CDMOs with the most regulatory evidence on file

Olon
Rodano (Milano), Italy
11 FDA inspections · 44 EMA/MHRA GMP certs
Last FDA inspection: 2026-01-16 · VAI
See the evidence →
FUJIFILM Diosynth Biotechnologies
86.7
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
0 FDA inspections · 35 EMA/MHRA GMP certs
Last FDA inspection: None on file
See the evidence →
Piramal Pharma Solutions
86.9
Lexington, KY · Riverview, MI · Ahmedabad, IN
7 FDA inspections · 15 EMA/MHRA GMP certs
Last FDA inspection: 2026-02-13 · VAI
See the evidence →
Corden Pharma
83.1
Plankstadt, DE · Caponago, IT · Boulder, CO
5 FDA inspections · 17 EMA/MHRA GMP certs
Last FDA inspection: 2025-11-14 · NAI
See the evidence →
Curia (RNA/Advanced)
79.5
Albany, NY · Albuquerque, NM
2 FDA inspections · 18 EMA/MHRA GMP certs
Last FDA inspection: 2025-12-02 · NAI
See the evidence →
71
CDMOs tracked
28
Fully scored
37
With FDA records
105
FDA inspections
235
EMA/MHRA GMP certs
3
Warning letters

Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.

Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.

FDA inspection outcomes across these CDMOs: 32 NAI (no action), 72 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: Italy (78), United States (43), Germany (34), UNITED KINGDOM (32), Denmark (29).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PC
Kalamazoo, MI · McPherson, KS
Fully evidenced
Also makes its own products
90.1 100.0 4 insp · 14 GMP 2025-12-16 · NAI — 366 programs
2
PR
Lexington, KY · Riverview, MI · Ahmedabad, IN
86.9 96.0 7 insp · 15 GMP 2026-02-13 · VAI — —
3
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
4
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
5
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
83.1 99.3 5 insp · 17 GMP 2025-11-14 · NAI — —
6
RB
Hamburg, Germany
82.9 100.0 0 insp · 9 GMP None on file — —
7
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
8
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
9
EF
Planegg, DE · San Diego, CA
81.6 100.0 7 insp · 0 GMP 2026-05-15 · NAI — —
10
EK
Birmingham, AL · Vancouver, BC
81.5 99.8 2 insp · 2 GMP 2025-09-11 · NAI — —
11
NW
Vilnius, LT; Waltham (MA), USA
Hiring · 16 open roles
80.8 100.0 0 insp · 8 GMP None on file Available —
12
SG
Bengaluru, India
Hiring · 4 open roles
80.3 100.0 3 insp · 0 GMP 2025-02-20 · NAI — —
13
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
14
CRA
Albany, NY · Albuquerque, NM
Hiring · 48 open roles
79.5 100.0 2 insp · 18 GMP 2025-12-02 · NAI — —
15
AV
Tustin, CA
Hiring · 36 open roles
78.9 100.0 1 insp · 0 GMP 2025-05-29 · NAI — —
16
Oklahoma City, OK
78.6 98.2 1 insp · 0 GMP 2026-06-17 · VAI Available —
17
PG
Berlin, DE
78.1 100.0 0 insp · 4 GMP None on file — —
18
BT
Charlottetown, PE, Canada
76.5 99.4 1 insp · 0 GMP 2022-08-26 · VAI — —
19
KD
Woodbury, MN
76.1 98.5 3 insp · 9 GMP 2025-11-13 · VAI — —
20
AF
Charlottesville, VA
Hiring · 9 open roles
75.2 96.5 3 insp · 1 GMP 2024-05-08 · VAI — —
21
GM
Grand Rapids, MI
Hiring · 9 open roles
74.4 92.1 4 insp · 0 GMP 2025-11-04 · VAI — —
22
SI
Bloomington, IN · Halle, DE
Hiring · 93 open roles
74.3 91.8 0 insp · 1 GMP None on file
Warning letter 2026-03-03
— —
23
PBI
Pennington, NJ · Nanjing, CN
64.0 — — None on file — —
24
AU
63.0 — — None on file — —
25
HP
63.0 — — None on file — —
26
SS
Bloomington, IN
59.0 — — None on file — —
27
CU
South San Francisco, CA
Platform provider
56.5 — — None on file — —
28
IC
56.5 — — None on file — —
—
Rodano (Milano), Italy
Also makes its own products
Profiled — 11 insp · 44 GMP 2026-01-16 · VAI — —
—
Alès, France
Also makes its own products
Profiled — 1 insp · 2 GMP 2022-09-23 · VAI — —
—
Germany
Profiled — 2 insp · 2 GMP 2023-09-08 · VAI — —
—
Oklahoma City, Oklahoma, USA
Profiled — — None on file — —
—
Lin-gang, Shanghai, China
Profiled — — None on file — —
— Profiled — 1 insp · 0 GMP 2025-01-24 · NAI — —
—
Plantation, Florida, USA
Profiled — — None on file — —
—
Amsterdam, Netherlands; Brussels, Belgium
Also makes its own products
Profiled — 0 insp · 6 GMP None on file — —
—
India (registered sites)
Also makes its own products
Profiled — 5 insp · 1 GMP 2025-03-14 · NAI — —
—
Italy (Barga / Bolognana, Lucca); USA (Melville, NY)
Also makes its own products
Profiled — 3 insp · 0 GMP 2025-04-30 · NAI — —
— Profiled — 2 insp · 0 GMP 2025-05-14 · NAI — —
—
India
Profiled — 0 insp · 1 GMP None on file — —
—
South Korea
Also makes its own products
Profiled — 1 insp · 0 GMP 2024-07-23 · VAI — —
—
Spain
Also makes its own products
Profiled — 1 insp · 3 GMP 2022-10-26 · VAI — —
—
Bedford, NH, United States · Tredegar, United Kingdom
Hiring · 100+ open roles
Profiled — 3 insp · 4 GMP 2026-06-10 · VAI — —
— Profiled — 3 insp · 0 GMP 2026-06-30 · VAI — —
—
Germany
Also makes its own products
Profiled — 2 insp · 1 GMP 2024-10-19 · VAI — —
—
Poland
Hiring · 7 open roles
Profiled — 1 insp · 11 GMP 2023-06-23 · VAI — —
— Profiled — 0 insp · 5 GMP None on file — —
—
United States
Also makes its own products
Profiled — 1 insp · 0 GMP 2025-05-02 · OAI
Warning letter 2025-10-10
— —
—
Switzerland
Profiled — 1 insp · 0 GMP 2025-04-17 · VAI — —
—
United States
Profiled — — None on file — —
—
North Chicago, Illinois, United States
Also makes its own products
Profiled — 7 insp · 0 GMP 2025-12-16 · VAI — —
—
Ahmedabad, Gujarat, India
Also makes its own products
Profiled — 0 insp · 1 GMP None on file — —
—
Aprilia, Latina, Italy
Also makes its own products
Profiled — 2 insp · 0 GMP 2024-11-21 · VAI — —
—
Incheon, South Korea
Also makes its own products
Profiled — 0 insp · 1 GMP None on file — —
—
Osong, Cheongju, South Korea
Profiled — — None on file — —
—
Tokyo, Japan
Also makes its own products
Profiled — 1 insp · 0 GMP 2026-02-13 · VAI — —
—
Incheon, South Korea
Profiled — — None on file — —
—
Nerviano (Milan), Italy
Profiled — 1 insp · 4 GMP 2024-09-13 · VAI — —
—
Uetersen, Schleswig-Holstein, Germany
Also makes its own products
Profiled — 2 insp · 3 GMP 2025-02-13 · VAI — —
—
Istanbul, Turkey
Also makes its own products
Profiled — 1 insp · 0 GMP 2023-03-17 · VAI — —
—
Busan, South Korea
Also makes its own products
Profiled — — None on file — —
—
Hwaseong, Gyeonggi, South Korea
Also makes its own products
Profiled — — None on file — —
—
Seoul, South Korea
Also makes its own products
Profiled — — None on file — —
—
Visakhapatnam, Andhra Pradesh, India
Also makes its own products
Profiled — — None on file — —
—
Ikeda, Gifu, Japan
Profiled — — None on file — —
—
Rehovot, Israel
Also makes its own products
Profiled — — None on file — —
—
Caponago, Monza e Brianza, Italy
Also makes its own products
Profiled — — None on file — —
—
Tanzi, Taichung, Taiwan
Also makes its own products
Profiled — — None on file — —
—
Oss, Noord-Brabant, Netherlands
Profiled — — None on file — —
—
York, Pennsylvania, USA
Profiled — — None on file — —
—
Hukou, Hsinchu County, Taiwan
Also makes its own products
Profiled — — None on file — —
How we score CDMOs →

What to evaluate in a Biologics / mAb CDMO

Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.

Which biologics CDMOs handle mammalian vs microbial expression?

Biologics manufacturing splits along expression platform: mammalian (CHO, HEK) for monoclonal antibodies, Fc-fusions, and bispecifics; microbial (E. coli, Pichia) for smaller proteins, peptides, and some recombinant fragments. Most biologics CDMOs specialize in one platform; large diversified CDMOs like Lonza and Pfizer CentreOne run both. Individual CDMO profile pages flag platform coverage under the modality tags. Sponsors should confirm not just platform presence but validated batch scale and comparability data on the target expression system.

Commercial-scale biologics — who has the depth?

Commercial-scale biologics manufacturing requires validated production at 2,000L, 5,000L, and increasingly 20,000L single-use or stainless. The commercial-scale biologics filter surfaces CDMOs with top-quartile Signal Score or broad ClinicalTrials.gov footprint. Sponsors evaluating for BLA and commercial supply should verify recent FDA inspection classifications specifically on the biologics facility slated for their program — a Warning Letter on one site should not disqualify a CDMO with clean records elsewhere, but does require targeted diligence on the specific facility.

How to compare biologics CDMO quality records

The Quality Compliance pillar (35% of the composite) is the most decisive signal for biologics CDMO selection. Key components: recent FDA inspection classifications (NAI is clean, VAI indicates minor findings, OAI signals significant issues), Warning Letter history, and EMA and MHRA GMP certificate coverage. On individual CDMO profile pages, each 483 observation is dated and enumerated. Sponsors running a competitive bid should build a quality scorecard using these primary-source counts rather than relying on the CDMO's own summary — the underlying data is public and auditable.

How CDMO Signal computes the biologics ranking

The biologics Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications, Warning Letter history, and EMA/MHRA GMP density. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint. Financial Stability (20%) carries real weight for biologics specifically — this is a capital-intensive, long-cycle modality where parent-company backing bears on whether a CDMO will be operationally reliable through a 3–5 year commercial engagement; it draws on public/private status and parent-company backing. Capacity Intelligence (20%) counts the manufacturing sites and modalities listed on the profile; job postings are not a score input. Press announcements and SEC filings are shown on profiles as company signals and do not change any score. Full weightings at cdmosignal.com/methodology.

Bispecific antibody manufacturing — which CDMOs have the depth?

Bispecifics are the fastest-growing biologics segment, with distinct manufacturing challenges beyond standard mAb work: chain mispairing (managed via knob-in-hole, CrossMab, or DuoBody architectures), higher aggregation propensity requiring additional downstream steps, and specialized analytics for correct-pair confirmation. CDMOs with genuine bispecific depth typically have qualified purification trains beyond standard Protein A + polish, and have handled programs across at least two different bispecific architectures. Larger diversified CDMOs — Lonza, Samsung Biologics, WuXi Biologics, Boehringer Ingelheim — have led here; a subset of specialized CDMOs (KBI Biopharma, ProBioGen) are notable for engineering-heavy bispecific work. Sponsors should verify aggregate content specs at commercial scale and correct-pair confirmation via LC-MS or capillary IEF.

Biosimilar manufacturing — CDMO capabilities and regulatory pathway

Biosimilar manufacturing has a distinct regulatory profile: comparability to the reference product is the primary approval criterion, not novel efficacy demonstration. This creates specific CDMO requirements — analytical characterization depth (typically 30+ orthogonal methods), forced degradation programs, and Phase 3 comparability trial supply capability. CDMOs with biosimilar depth include Samsung Biologics (multiple approved biosimilars), Biocon Biologics, Celltrion (in-house + partner), Boehringer Ingelheim, Sandoz. Sponsors developing biosimilars should verify not just biologics capability but demonstrated regulatory pathway experience — specifically approved biosimilar filings under FDA 351(k) or EMA biosimilar pathway. Cost dynamics are also tighter than novel biologics; CDMOs experienced in this segment typically have cost-optimized workflows.

Single-use vs stainless steel — CDMO facility architecture matters

The choice between single-use bioreactor (SUB) systems and stainless steel affects capital, scheduling flexibility, and validation approach. Single-use dominates clinical and early commercial supply (2,000L single-use is now the norm) — faster changeover, no cleaning validation, lower capex, and better multi-product capacity utilization. Stainless steel remains dominant at true commercial scale (10,000L+ for high-volume products like Humira/adalimumab), where the capex is justified by predictable multi-year campaigns. Some CDMOs have converted entirely to single-use (Samsung Biologics Plant 4 is 8×15,000L stainless, but their Plant 5 is single-use focused); others operate hybrid facilities. Sponsors should match their product's projected annual demand to the CDMO's most economically appropriate architecture — asking a stainless steel CDMO to run at 2,000L will typically cost more than an SUB-optimized site.

How to structure a biologics CDMO RFP — a 6-step buyer framework

For sponsors running competitive biologics CDMO selection: 1. Expression platform + cell line strategy — CHO, HEK, or microbial; CDMO's own cell line vs your cell line; typical titer benchmarks at bioreactor scale. 2. Scale ladder — validated bioreactor scale that matches your intended clinical and commercial demand (2,000L single-use is standard clinical; 15,000L stainless is standard commercial for high-volume mAbs). 3. Quality track record — FDA inspection classifications on the specific facility slated for your program (see ranked table above), Warning Letter history, EMA/MHRA GMP certificate density. 4. Downstream process — standard Protein A + polish sufficient, or does your product need extended purification for aggregate/impurity control. 5. Fill-finish integration — same site, same CDMO group, or coordinated separately (affects timelines and comparability). 6. Financial stability — parent-company health matters for biologics because commercial engagements are 3-5 year commitments; SEC filings and M&A announcements are context worth reviewing, but they are company announcements and do not change any score. The methodology page explains how Signal Score is computed.

Biologics / mAb CDMOs — Frequently Asked Questions

How many Biologics / mAb CDMOs have FDA inspection records?
CDMO Signal tracks 37 Biologics / mAb CDMOs with FDA inspection records and 235 EMA/MHRA GMP certificates across the group.
What should I look for in a biologics CDMO?
Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.
What is the difference between a biologics CDMO and a cell or gene therapy CDMO?
Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Biologics shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Recombinant Proteins CDMOs mRNA / LNP CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector